• Nkarta (NASDAQ:NKTX) is ending development of NKX019 in non-Hodgkin lymphoma. However, the candidate will continue to advance for autoimmune disease indications.
• The company said that the decision was made based on an assessment of the latest group of large B-cell lymphoma patients in a trial.
• NKX019 targets the CD19 protein. It is currently in the clinic under examination as a lupus treatment.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.